Skip to main content Accessibility help
×
Home
  • Print publication year: 2010
  • Online publication date: May 2010

3 - Digestive and metabolic physiology of obesity

from Section 1 - Pathophysiology

References

1. SchwarzJM, LinfootP, DareD, AghajanianK. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003; 77: 43–50.
2. JuurinenL, KotronenA, GranerM, Yki-JarvinenH. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. J Clin Endocrinol Metabol 2008; 93: 118–24.
3. RaperHS, SmithEC. The direct action of insulin on fat metabolism. J Physiol 1925; 60: 41–9.
4. HollingsworthKG, AbubackerMZ, JoubertI, AllisonMED, LomasDJ. Low-carbohydrate diet induced reduction of hepatic lipid content observed with a rapid non-invasive MRI technique. Br J Radiol 2006; 79: 712–5.
5. PetersenKF, DufourS, BefroyD, LehrkeM, HendlerRE, ShulmanGI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54: 603–8.
6. KotronenA, Yki-JarvinenH. Fatty liver: A novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27–38.
7. SattarN, McConnachieA, FordI, et al. Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland Coronary Prevention Study: Specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 2007; 56: 984–91.
8. ShibataM, KiharaY, TaguchiM, TashiroM, OtsukiM.Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007; 30: 2940–4.
9. SchindhelmRK, DekkerJM, NijpelsG, HeineRJ, DiamantM. No independent association of alanine aminotransferase with risk of future type 2 diabetes in the Hoorn study. Diabetes Care 2005; 28: 2812.
10. EkstedtM, FranzenLE, MathiesenUL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865–73.
11. BrowningJD, SzczepaniakLS, DobbinsR, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387–95.
12. AdamsLA, AnguloP, LindorKD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899–905.
13. Neuschwander-TetriBA, CaldwellSH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202–19.
14. MollerDE, KaufmanKD. Metabolic syndrome: A clinical and molecular perspective. Annu Rev Med 2005; 56: 45–62.
15. DayCP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med 2006; 6: 19–25.
16. AdamsLA, SandersonS, LindorKD, AnguloP. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132–8.
17. DayCP, JamesOF. Steatohepatitis: a tale of two “hits”?Gastroenterology 1998; 114: 842–5.
18. BruntEM, JanneyCG, Di BisceglieAM, Neuschwander-TetriBA, BaconBR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467–74.
19. KleinerDE, BruntEM, VanNM, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21.
20. MartynJA, KanekiM, YasuharaS. Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms. Anesthesiology 2008; 109: 137–48.
21. BodenG. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3.
22. WangY, RimmEB, StampferMJ, WillettWC, HuFB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 2005; 81: 555–63.
23. YusufS, HawkenS, ÈunpuuS, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366: 1640–9.
24. PischonT, BoeingH, HoffmannK, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: 2105–20.
25. ReavenGM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607.
26. AlbertiKG, ZimmetPZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539–53.
27.Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood pressure in adults (Adult Treatment Panel III): final report. Circulation 2002; 106: 3143.
28. GrundySM, BrewerHB, CleemanJI, SmithSC, LenfantC. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association. Circulation 2004; 109: 433–8.
29. GrundySM, CleemanJI, DanielsSR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–52.
30. GrundyS, HansenB, SmithS.AHA/NHLBI/ADA conference proceedings: clinical management of metabolic syndrome. Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management. Circulation 2004; 109: 551.
31. FordE, GilesW. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003; 26: 575.
32. FordES, GilesWH, MokdadAH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004; 27: 2444–9.
33. KarelisAD, St PierreDH, ConusF, Rabasa-LhoretR, PoehlmanET: Metabolic and body composition factors in subgroups of obesity: what do we know?J Clin Endocrinol Metab 2004; 89: 2569–75.
34. KipKE, MarroquinOC, KelleyDE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: A report from the Women's Ischemia Syndrome Evaluation (WISE) Study. Circulation 2004; 109: 706–13.
35. KohKK, HanSH, QuonMJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Amer Coll Cardiol 2005; 46: 1978–85.
36. PischonT, GirmanCJ, HotamisligilGS, RifaiN, HuFB, RimmEB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730–7.
37. PaiJK, PischonT, MaJ, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599–610.
38. RidkerPM, RifaiN, PfefferM, SacksF, LepageS, BraunwaldE.Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149–53.
39. HamaguchiM, KojimaT, TakedaN, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722–8.
40. GirmanC, RhodesT, MercuriM. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136.
41. McNeillAM, KatzR, GirmanCJ, et al. Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study. J Am Geriatr Soc 2006; 54: 1317–24.
42. SundstromJ, RiserusU, BybergL, ZetheliusB, LithellH, LindL. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006; 332: 878–82.
43. HuangKC, LeeLT, ChenCY, SungPK. All-cause and cardiovascular disease mortality increased with metabolic syndrome in Taiwanese. Obesity (Silver Spring) 2008; 16: 684–9.
44. WilsonPW, D’AgostinoRB, PariseH, SullivanL, MeigsJB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066–72.
45. MozaffarianD, KamineniA, PrineasRJ, SiscovickDS. Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med 2008; 168: 969–78.
46. DekkerJM, GirmanC, RhodesT, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666–73.
47. KurlS, LaukkanenJA, NiskanenL, et al. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 2006; 37: 806–11.
48. GrundySM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006; 5: 295–309.
49. PanW, HindlerK, LeeVV, VaughnWK, CollardCD. Obesity in diabetic patients undergoing coronary artery bypass graft surgery is associated with increased postoperative morbidity. Anesthesiology 2006; 104: 441–7.
50. BirkmeyerNJ, CharlesworthDC, HernandezF, et al. Obesity and risk of adverse outcomes associated with coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 1998; 97: 1689–94.
51. JinR, GrunkemeierGL, FurnaryAP, HandyJR, Jr. Is obesity a risk factor for mortality in coronary artery bypass surgery?Circulation 2005; 111: 3359–65.
52. KimJ, HammarN, JakobssonK, LuepkerRV, McGovernPG, IvertT.Obesity and the risk of early and late mortality after coronary artery bypass graft surgery. Am Heart J 2003; 146: 555–60.
53. ReevesBC, AscioneR, ChamberlainMH, AngeliniGD. Effect of body mass index on early outcomes in patients undergoing coronary artery bypass surgery. J Amer Coll Cardiol 2003; 42: 668–76.
54. PrabhakarG, HaanCK, PetersonED, CoombsLP, CruzzavalaJL, MurrayGF. The risks of moderate and extreme obesity for coronary artery bypass grafting outcomes: a study from the Society of Thoracic Surgeons' database. Ann Thorac Surg 2002; 74: 1125–30.
55. AlexanderCM, LandsmanPB, TeutschSM, HaffnerSM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210–4.
56. EagleKA, BergerPB, CalkinsH, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery – executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Amer Coll Cardiol 2002; 39: 542–53.
57. ManganoDT, LayugEL, WallaceA, TateoI. The Multicenter Study of Perioperative Ischemia Research Group: Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med 1996; 335: 1713–21.
58. PoldermansD, BoersmaE, BaxJJ, et al. The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group: The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 1999; 341: 1789–94.
59. FleisherLA, BeckmanJA, BrownKA, et al. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: Focused update on perioperative beta-blocker therapy. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2002 guidelines on perioperative cardiovascular evaluation for noncardiac surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology. J Amer Coll Cardiol 2006; 47: 2343–55.
60. DevereauxPJ, GoldmanL, CookDJ, GilbertK, LeslieK, GuyattGH. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005; 173: 627–34.
61. EagleKA, BergerPB, CalkinsH, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol 2002; 39: 542–53.
62. YangH, RaymerK, ButlerR, ParlowJ, RobertsR. The effects of perioperative [beta]-blockade: Results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J 2006; 152: 983–90.
63. PoldermansD, BaxJJ, KertaiMD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003; 107: 1848–51.
64. JuulAB, WetterslevJ, GluudC, et al. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. BMJ 2006; 332: 1482.
65. LindenauerPK, PekowP, WangK, MamidiDK, GutierrezB, BenjaminEM: Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005; 353: 349–61.
66. DevereauxPJ, YangH, YusufS, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371: 1839–47.
67. HindlerK, ShawAD, SamuelsJ, FultonS, CollardCD, RiedelB. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 2006; 105: 1260–72.
68. LindenauerPK, PekowP, WangK, GutierrezB, BenjaminEM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004; 291: 2092–9.
69. O’Neil-CallahanK, KatsimaglisG, TepperMR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol 2005; 45: 336–42.
70. KapoorAS, KanjiH, BuckinghamJ, DevereauxPJ, McAlisterFA. Strength of evidence for perioperative use of statins to reduce cardiovascular risk: systematic review of controlled studies. BMJ 2006; 333: 1149.
71. DurazzoAE, MachadoFS, IkeokaDT, De et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004; 39: 967–75.
72. HeeschenC, HammCW, LaufsU, SnapinnS, BohmM, WhiteHD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446–52.
73. SpencerFA, AllegroneJ, GoldbergRJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004; 140: 857–66.
74. LeMY, GodetG, CoriatP, et al. The impact of postoperative discontinuation or continuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg 2007; 104: 1326–33.
75. SchoutenO, HoeksSE, WeltenGM, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007; 100: 316–20.
76. LipshutzAK, GropperMA. Perioperative glycemic control: an evidence-based review. Anesthesiology 2009; 110: 408–21.
77. BaranovD, NeliganP: Trauma and aggressive homeostasis management. Anesthesiol Clin 2007; 25: 49–63, viii.
78. JeschkeMG, KleinD, BolderU, EinspanierR. Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology 2004; 145: 4084–93.
79. TakebayashiK, AsoY, InukaiT. Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes. Metabolism 2004; 53: 693–9.
80. StentzFB, UmpierrezGE, CuervoR, KitabchiAE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004; 53: 2079–86.
81. JeschkeMG, KleinD, BolderU, EinspanierR. Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology 2004; 145: 4084–93.
82. JeschkeMG, EinspanierR, KleinD, JauchKW. Insulin attenuates the systemic inflammatory response to thermal trauma. Mol Med 2002; 8: 443–50.
83. JonassenAK, SackMN, MjosOD, YellonDM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001; 89: 1191–8.
84. ChaudhuriA, JanickeD, WilsonMF, et al. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 2004; 109: 849–54.
85. JonassenAK, SackMN, MjosOD, YellonDM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001; 89: 1191–8.
86. LazarHL, ChipkinSR, FitzgeraldCA, BaoY, CabralH, ApsteinCS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004; 109: 1497–502.
87. Van den Berghe G, WoutersP, WeekersF, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359–67.
88. FinneySJ, ZekveldC, EliaA, EvansTW. Glucose control and mortality in critically ill patients. JAMA 2003; 290: 2041–7.
89. ZerrKJ, FurnaryAP, GrunkemeierGL, BookinS, KanhereV, StarrA. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 1997; 63: 356–61.
90. FurnaryAP, ZerrKJ, GrunkemeierGL, StarrA. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67: 352–60.
91. FurnaryAP, GaoG, GrunkemeierGL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003; 125: 1007–21.
92. LangoucheL, VanhorebeekI, VlasselaersD, et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 2005; 115: 2277–86.
93. VanhorebeekI, De VosR, MesottenD, WoutersPJ, Wolf-PeetersC, Van den Berghe G. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet 2005; 365: 53–9.
94. Van den Berghe G, WoutersPJ, BouillonR, et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 2003; 31: 359–66.
95. Van den Berghe G, WilmerA, HermansG, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449–61.